Physician profile
Lori Day
NPI 1992268981
$1,020.63
in general payments reported to CMS, 2019-2025
24 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.05 · 2023: $11.59 · 2024: $376 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $123.85 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $117.58 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $95.62 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $84.76 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $83.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $75.59 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.96 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $49.72 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $42.84 | 2025 | |
| Organogenesis INC. | $28.05 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $25.96 | 2025 | |
| Astellas Pharma US INC | $23.65 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $21.69 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $19.98 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $17.87 | 2024 | Trelegy Ellipta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.74 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $17.64 | 2024 | |
| Corium, LLC | $17.49 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $16.37 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $16.35 | 2025 | Auvelity |
| Tris Pharma INC | $15.84 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $14.27 | 2024 | Gardasil 9, M-M-R II, Gardasil |
| Idorsia Pharmaceuticals US INC | $13.24 | 2024 | Quviviq |
| Organon LLC | $11.59 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.